On March 3, 2026, Williams & Connolly client Genevant Sciences, a subsidiary of Roivant Sciences Ltd., and Arbutus Biopharma Corporation secured a global settlement worth up to $2.25 billion against Moderna in a patent suit over Moderna's COVID-19 vaccines. This follows the U.S. District Court for the District of Delaware’s decisions denying Moderna’s motion for summary judgment, granting in part Genevant’s motion for summary judgment, and excluding from trial substantial portions of Moderna’s damages expert opinion. This win also resulted from the court’s earlier claim construction decision, which construed three of the four disputed claim terms in Genevant’s favor, including the principal term that partner David Berl argued before the court.
The Williams & Connolly team includes David Berl, Adam Harber, Shaun Mahaffy, Andrew Hoffman, Matthew Lachman, Arthur Argall III, Falicia Elenberg, Phil Haunschild, and Kathryn Larkin.